About BRRISK

BRRISK uses a validated model (BOADICEA developed by University of Cambridge, Department of Public and Primary Care) to stratify risk of breast cancer.

The BOADICEA algorithm is the first comprehensive model that allows for reliable breast cancer risk prediction in unaffected women. It draws on mutation screening information for rare (high risk and moderate risk) breast cancer genetic susceptibility variants, explicit family history, personal lifestyle, hormonal and reproductive risk factors, and mammographic density.

Patients enter their information into a web-based application, which is intuitive and friendly to use. Patients will present you with a report for your consult.

Stratification into population, moderate or high risk helps you triage patients into the right surveillance or referral pathway.

A BRRISK assessment is not designed to replace mammographic screening.

Benefits of BRRISK

• Stratify your patients according to risk
• Understanding risk ensures women are be monitored for breast cancer
• Specialists see those women who really need to be seen
• BRRISK is aligned to evidence based guidelines
• Patient education about breast cancer

In addition

• Patients personal data is protected by New Zealand privacy laws
• Data is saved in a secure environment in New Zealand
• Patients are empowered to understand their own level of risk
• Patients manage their own data

Sharing of personal data

New Zealand Family Cancer Service will only share de-identified data with researchers affiliated with New Zealand universities. We only support research that aims to improve outcomes for women with breast cancer or will assist in the further development of BRRISK for all communities in Aotearoa New Zealand.

This patient profile captures information under the following sections and is used by BRRISK to produce a risk assessment report.

• personal
• lifestyle
• women’s health
• children
• breast screening
• medical history
• family history

This form is for demonstration purposes only. Information entered will not be saved, nor will it calculate a risk assessment.

View patient profile form

We invite health professionals wishing for live introduction to BRRISK to make a booking using the scheduler below.

• Li SX, Milne RL, Nguyen-Dumont T, Wang X, English DR, Giles GG, et al. Prospective Evaluation of the Addition of Polygenic Risk Scores to Breast Cancer Risk Models. JNCI Cancer Spectr. 2021;5 doi:10.1093/jncics/pkab021 validation study

• Lakeman IMM, Rodríguez-Girondo M, Lee A, Ruiter R, Stricker BH, Wijnant SRA, et al. Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort. Genet Med. 2020;22:1803–1811. validation study

• Parichoy Pal Choudhury et al. Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. Breast Cancer Research 23, 22 (2021). validation study

• Hurson AN, Pal Choudhury P, Gao C, Hüsing A, Eriksson M, Shi M, et al. Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. Int J Epidemiol. 2021; doi:10.1093/ije/dyab036 validation study

• Carver, T. et al. CanRisk Tool—A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants. Cancer Epidemiol Biomarkers Prev (2020).
• Archer, S. et al. Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study. PLoS ONE 15, e0229999 (2020)
• Mavaddat, N. et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. The American Journal of Human Genetics 104, 21–34 (2019).
• Lee, A. et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med 21, 1708–1718 (2019).
• Carver, T. et al. pedigreejs: a web-based graphical pedigree editor. Bioinformatics 34, 1069–1071 (2018).
• Lee, A. J. et al. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Genet. Med. 18, 1190–1198 (2016).
• Jervis, S. et al. A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects. Journal of Medical Genetics 52, 465–475 (2015).
• Lee, A. J. et al. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br. J. Cancer 110, 535–545 (2014).
• MacInnis, R. J. et al. Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre. British Journal of Cancer 109, 1296–1301 (2013).
• Mavaddat, N. et al. Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 21, 134–147 (2012).
• Cunningham, A. P., Antoniou, A. C. & Easton, D. F. Clinical software development for the Web: lessons learned from the BOADICEA project. BMC Medical Informatics and Decision Making 12, 30 (2012).
• Mavaddat, N., Rebbeck, T. R., Lakhani, S. R., Easton, D. F. & Antoniou, A. C. Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Research 12, R28 (2010).
• Antoniou, A. C. et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. Journal of Medical Genetics 45, 425–431 (2008).
• Barcenas, C. H. et al. Assessing BRCA Carrier Probabilities in Extended Families. JCO 24, 354–360 (2006).
• Antoniou, A. C. & Easton, D. F. Risk prediction models for familial breast cancer. Future Oncol 2, 257–274 (2006).
• Antoniou, A. C. et al. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Research 8, R3 (2005).
• Antoniou, A. C. et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. British Journal of Cancer 98, 1457–1466 (2008).
• Antoniou, A. C., Pharoah, P. P. D., Smith, P. & Easton, D. F. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. British Journal of Cancer 91, 1580–1590 (2004).